New cancer drug kinder than chemotherapy
bbc.com
bbc.com
There's not enough data to say if the immune therapy is helping (he's on traditional low-dose chemo as well), but it seems promising. The company (Torigen.com) is focused on animal treatment for now, but sees applications for humans in the future.
> one of the most common ways to treat cancer is radiation therapy with x-rays ... You can use these highly energetic photons to kill off cancer cells. The difficulty really is ... killing the cancer cells without killing the patient - but the problem with using x-rays is that you can't shoot them at tumors inside the body without also burning some of the tissue on the way to the tumor and behind it... But you can use beams of other particles instead and this is where particle physics enters ... A beam of protons is far less likely to interact with tissue on short distances
And it is still part of the "kinder" set (protons are "kinder" than x-rays).
New Cancer Treatment With Proton Flashes Goes on Trial
Particle beams for cancer therapy aren't new; shortly after the invention of the cyclotrone, EO Lawrence did this with neutrons in the late 1940s and proton beams were being used successfully in the 50's. She leaves out these details and only mentions trials from the 1990s.
Just curious, since I've run into her channel recently and found her generally pleasant and informative (minus the unfunny jokes part), do you have any specific examples of this?
To be fair, her criticism isn't that LIGO itself was fake, but it's really hard to tell, from the video and from https://backreaction.blogspot.com/2019/09/whats-up-with-ligo... If you read that blog, you can see she is using a collection of rhetorical techniques to cast down on the LIGO results (for example, using the term retraction out of context).
But it's mainly her videos about health-related stuff that doesn't have good support. She approaches most of these things with a "assume a spherical cow" approach, common when physics folks try to do biology.
but we have not effected any blind endorsement. Just informed of a consistent parallel piece, esp. after the coincidence, which may be useful in itself - or just interesting.
Patients still suffer adverse reactions, and you will have margins of error, not to mention you do not have unlimited time to develop a treatment plan that is perfect. It's a time/efficacy trade off and the goal is to hit as much of the cancer as possible, while maintaining a SAFE dose of radiation, not a zero dose. What is a safe dose? Well, the more aggressive your cancer the higher that number gets too.
Some patients still receive high dose radiation while on proton treatment simply because their cancer is that aggressive, typically suffering the same grade 1-2 diarrhea and vomiting as any other form of radiation.
Proton treatment is far superior for most cancers, especially deeper cancers like colon and prostate.
It's a living example of how tragic a new treatment option is, unfortunately proton centers are expensive to build and take years. So many people are still passing away from treatable disease and having to endure high dose chemotherapy in other cases.
That's exactly what many of the new immunotherapies do.
Disclaimer: I am not a doctor or medical physicist, I’m just fortunate enough to briefly use a machine intended for this purpose in separate nuclear physics studies. I believe BNCT has been done before with reactor sources of neutrons, but for some reason not as a standard treatment and there’s only one left in Taiwan for this purpose. The new development, afaik, is the ability to use accelerator neutron sources for this. Would love it if anybody knows more!
/knows nothing about physics
Do a websearch about MIMO and beamforming, or ask Bing chatgpt to explain it.
The longer answer is something called The Superposition Principle. Essentially, waves (photons) pass through one another. The amplitude adds, but only at the intersection. The frequency does not change. (Consider the laser as the ultimate example of this)
(Side note: The superposition principle does not always hold; however, the realms where the addition of MOAR PHOTONZ becomes non-linear are broadly incompatible with life)
So, most techniques involve having many, many beams intersect so that the individual paths are only a little damaged while a specific spot where they all meet takes the hit. I met someone who specifically programs the machines that do this because there's a lot of math involved chucking radiation around irregular hunks of blood, meat, and bone, and the calculations are done because the first idea of "just cross the streams" works fine in a vacuum, but not so much in the human body.
Flash therapy is the part is which just now entering clinical trials, where you treat the patient with ultra-high dose rates (so you deliver the same dose of radiation, but in maybe 90 ms instead of 90 seconds). There are indications that healthy cells are better at recovering from the ulra-high dose rate than tumor cells are, which means it would have a protective effect on healthy tissue, but the mechanism behind it is not known. The type of radiation is not specified, it can be protons, electrons, x-rays, etc.
So "proton flash therapy" is a Flash therapy that uses protons. Other clinical trials are using electrons instead, i.e. "electron flash therapy".
What are the theories as to why healthy cells recover better than tumor cells, if any?
I really want to do whole-body clonal work. Our bodies and genes are machines, yet we still haven't put them to work. We're plastering over the breaks with crude tools that feel like modern day bloodletting. The blast radius in the transduction pathways is huge and imprecise.
I've written extensively about this topic on HN. Give me a minute and I'll dig up some references.
Edit:
https://news.ycombinator.com/item?id=35321368
Actual cancer treatments are moving forward at a good pace. Immunotherapies are a good example. Cancer treatment is an example of medical research working well.
Not to mention issue of patient being weakened by, say, organ failure, to even survive such procedure.
You didn't "write extensively", you put science fiction plots ideas that have already been done a dozen times into comments.
I'm going to go out on a limb and say that execution might be a bigger factor than ideas here.
I originally posted a follow-up message, but I revealed to much of the path gradient to build this and so I deleted it. There are so many low-hanging fruit markets, but I have to hold my tongue. It needs the right leadership and angle of attack.
I bet my reputation that none of this is science fiction, though, and I can't wait to prove you wrong about everything you doubt me on. Give me ten years on this one. I'll show you.
The Hollywood thread you keep doubting me on is going to be extremely obvious in about six months. I really want to see you eat your hat on that one. I'm sleeping on the floor every night to make it happen, and we're getting there.
Also if you think there’s no sense of urgency, you haven’t talked to anyone actually in the field. Do you really think oncologists (pediatric oncologists!) aren't eager to cure their patients?
Even historic improvements for large demographics have massive returns. Keytruda (major oncology improvement) had more than $20 billion sales in 2023.
It is hard to think of a stronger market incentive to improve drugs as much as possible.
Don’t be bloody ridiculous.
Ok, can you explain what you meant by this?
These aren't "tiny wins". These are massive advancements in cancer treatment. And they're happening every decade or so, and added together is drastically changing outcomes.
This is one study.
"Cancer mortality decreased by 20.1% (95% uncertainty interval [UI], 18.2%-21.4%) between 1980 and 2014, from 240.2 (95% UI, 235.8-244.1) to 192.0 (95% UI, 188.6-197.7) deaths per 100 000 population."
Childhood cancer (mostly Leukemia) treatment in the USA is a well-organized country-wide clinical study aimed, at this point, at carefully reducing the amount of high-intensity chemo via replacing it with drugs like the one in the article, Blina.
They have gotten so good at treating Leukemia that they are now optimizing for reducing the long-term negative health impacts that come as a result of the treatment.
There are still tragic cases where the patients systems don't respond well, or there are complications as a result of compromised immune systems, but everything I have experienced points to major advancements and continued progress towards improving outcomes.
If we could find and repair DNA errors in normal cells, we could do it in cancerous cells as well. I don't think there's much of a difference.
I glean from many non-main stream sources (who are generally labeled quacks or naysayers, I have lost track of sources) :
- There have been almost no improvements in cancer treatments especially chemotherapy for _several_decades. Some sleight of hand involving some statistics and the fact that cancer can now be diagnosed in an at an earlier stage, means that the survival rate that is calculated by the survival of people Beyond 5 years of the first diagnosis, is higher.
- The primary approach to treating cancer (especially with chemotherapy and radiation) appears flawed. Cancer is a systemic disease so even if you destroy the tumor, you will have more of those propping up, because the body is already predisposed to creating them.
- It's a money making scam ( just like any other industry) that thrives in keeping a patient as sick as possible for as long as possible
-A lot of naive, but well intention people fall for the above three points mentioned.
Of course any attempt to even mention that people could be wrong would be retaliated with: you don't-care-for-people-dying response. Heroics generally trumps common sense
In the case of the family member in question it sounds like one of these therapies are an option after CAR-T treatment currently. But it might be a preferable option in the future. I'm not sure if that is related to novelty and lack of data or something else.
> When blinatumomab was approved, Amgen announced that the price for the drug would be US$178,000 per year, which made it the most expensive cancer drug on the market. Merck's pembrolizumab was priced at US$150,000 per year when it launched (in September 2014).[14] At the time of initial approval, only about 1,000 patients in the US had an indication for blinatumomab.
I take it they prefer to pump chemotherapy poison ito patients for financial reasons?
I mention it because in the UK people don’t really understand that drugs can be really expensive. The assumption is that due to the scale of the NHS they’re heavily discounted or even free, and that the high prices mentioned by US folk is due to the unusual healthcare situation there.
But there’s real money being paid by taxes, as well as procedures that determine whether you’re worth the expenditure.
But also:
> and that the high prices mentioned by US folk is due to the unusual healthcare situation there.
Are they wrong? I keep hearing that the US government spends more per person on healthcare than the UK government, even though the US also has mostly private insurance on top of that and the UK mostly doesn't?
The NHS probably does barter discounts. But consider that a discount of 50% off $150k/yr would be incredible, yet still be a vast amount of money for a single treatment.
The price the NHS pays for drugs is published in the BNF.
The price that the manufacturer charges for a course of blinatumomab (in a different indication for adults, not that this is especially relevant in this discussion) is ~£56k [0] - so significantly lower than the price quoted from the US.
NICE (the organisation which published the document referenced) exists to achieve value for money for the NHS for higher-priced and specialist treatments. If, following a thorough assessment, a medicine does not achieve the required value for money standard at the price proposed by the manufacturer, they are presented with two options: to not have the drug reimbursed in the UK at all, or to lower the effective price, so that the drug becomes cost-effective.
[0] https://www.nice.org.uk/guidance/ta589/documents/final-appra...
Which is effectively price controls, because the number of people with the money to pay out of pocket will be low, so the choice is essentially to sell at the regulated price or not at all. And the company would be crazy to choose the latter because the high cost is to pay for R&D, not manufacturing, so they'll never be better off to abandon the market than to take whatever they're offered.
Then you have prices being set by the political system. If the regulators get captured by pharma companies (as would be likely if implemented in the US) they'd overpay when the drug isn't worth it. If not, the regulators would have all the leverage and very little reason not to set prices too low, reducing the incentive for R&D and causing more people to die.
Yes, selling for cheap is better than not selling at all, but if the government entities keep being stingy, maybe next time the company won't develop a treatment for a rare disease at all because it's just not worth it...
Which is exactly the problem. And it's even worse than that, because it's a global market with national monopsony buyers. If your country is 4% of the global market, whatever you do isn't going to change the math for the drug company very much and you can ride on the coattails of other countries, so you might as well be as stingy as possible. But then everyone has the same incentive and the net effect is tragedy of the commons.
Or in practice, the US disproportionately funding drug development for the whole world and then people from other countries criticizing them for having higher drug prices.
And the quoted price is not the price insurers pay in the US either.
As someone who has worked in this space, the EU is lower than the US, but for oncology drugs the difference isn't that large.
https://www.pgpf.org/blog/2022/11/how-much-does-the-united-s...
> According to a 2021 study by the RAND Corporation, a non-profit global policy think tank, prices of prescription drugs in the U.S. are 2.4 times higher than the average prices of nine other nations (Austria, Australia, Belgium, Canada, Germany, Japan, Sweden, Switzerland and the United Kingdom). That higher cost is largely related to brand-name drugs, which are 4.9 times more expensive in the U.S. than in those countries. In fact, brand-name drugs are responsible for 84 percent of total drug costs in the United States despite accounting for only 8 percent of drugs dispensed.
The US is just starting to negotiate pricing, beginning with ten specific drugs. Until 2022, it was illegal for Medicare to do so.
https://www.hhs.gov/about/news/2023/10/03/biden-harris-admin...
You mean ones life is valued more if one has children?
And I made it sound mechanical, but AI has not taken over all decisions like this yet. I believe it’s a discussion between a team of doctors where they are considering the humanity and ethics of the situation as well as the cost. Like, what would be the impact on the child/dependent if the parent was to die, do they have another parent or family members they can live with, can they fend for themselves, etc.
I don't recall seeing having children as a variable in that valuation, it's typically more about how many years of work you continue to do, cast back into current dollars ("present value lifetime earnings", see https://escholarship.org/content/qt82d0550k/qt82d0550k.pdf?t...) and normalized for base rates.
But that has nothing to do with inherent value.
So, what I want to say is, assuming we follow this value of life calculation, I am more valuable than this whole family of three.
This isn't an argument about whether or not we should incentivize couples to have children (we absolutely should, in my opinion), but whether parents of young children should be prioritized for life saving treatment. Maybe I'm crazy, but I think the additional value of not leaving children parentless is worth including in the calculation.
I almost don't want to even know... if I find out it costs only ~$5 to develop a dose, and they're charging $200k to dying people... ugh
The flip side is that it treats a rare form of leukemia so the market isn't very big and since they can't lower the price enough to compete with chemo, they have to actually charge more to get their money back. For example chemo might cost $10k, but their drug costs $10k to make per person so if they charged $50k they might not even get enough customers to break even. So instead they charge $200k to get the most from the patients they can capture like the X% of patients who are allergic to the chemo drugs and have no choice (Just an example, I don't know the specifics for blinatumomab)
At the time I took blinatumomab, I had already had unsuccessful treatments with two different chemo regimens. At the hospital system I was at, at least one failed chemo regimen was a pre-requisite for blinatumomab, as it was only indicated for "refractory" or "recurrent" cancers. I assume this is more related to the chance of acute death and (at the time) relative newness of blinatumomab compared to established chemotherapy regimens. (B-cell ALL is sadly very common in children, but this fortunately means that there is a LOT of funding research into the disease.)
After going through 3 one-month cycles of blinatumomab, it was becoming less effective, but I was able to line up a allogenic stem cell transplant which has (knock on a thousand woods) kept me clean for the 8 years since.
In this review, it seems like only 2% of 189 blinatumomab patients got a grade 3 CRS (requires hospitalisation) and 0% a grade 4 CRS (requires ventilation).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142489
To me as a non impacted layman, the side effects of even one of the several chemotherapeutics one seems to get appear to be much more destructive, uncomfortable and scary than the well manageable CRS from blinatumomab that primarily appear in the first cycle.
Also looks like after blinatumomab, there are now also "Anti-CD19 CAR T cells" available which are even more effective (but have stronger side effects).
I hope I don't get cancer.
I'd be curious to know if people who have endured famines, controlled for age, have lower (and/or higher) rates of some cancers in certain phases of their lives.
Of course looking at the effect of famine on an adult populations would do more to investigate your hypothesis than the effect on developing children.
But famine seems a bit extreme, no? Aren’t there also regional studies that show regional dietary/nutritional factors that correlate with lower cancer rates?
Usually the cancer cells are concentrated where the tumor is. One of the first things they may do upon diagnosis of cancer is a PET scan (which shows you where cancerous stuff is throughout your body).
Life advice for all the young folks: don't get cancer.
metastatic cancer is a numbers game. for example. at stage 0-1, you might still have millions of cancer cells throughout your body, and there is a good chance your immune system can clean them up. At stages 2 or 3 there might be trillions of non-local cancer cells, with a proportionally greater chance of propagation.
We opted for surgical removal instead.
Radiation therapy can target specific areas. It's still used instead of chemo in some cases.
Interesting and extremely cheap.
Seems scientist did find benefits as well in various trials, examples (more can be though with Googling, e.g. I know of a study of the effects on breast cancer in mice):
- https://pubmed.ncbi.nlm.nih.gov/30093705/
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437363/
- https://baltimorepostexaminer.com/human-patients-are-given-f...
Not everyone has had success:
- https://karger.com/cro/article/14/2/886/820730/Drug-Induced-...